Olmes, Gregor Leonhard http://orcid.org/0009-0000-9334-4774
Doerk, Merle
Solomayer, Erich-Franz
Nigdelis, Meletios P.
Sima, Romina-Marina
Hamoud, Bashar Haj
Funding for this research was provided by:
Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
Article History
Received: 17 July 2023
Accepted: 8 November 2023
First Online: 11 December 2023
Declarations
:
: The authors declare the following conflict of interest. GL Olmes received grants form AstraZeneca (Cambridge, UK) and RG Ärztefortbildung GmbH, membership of DGGG (Berlin, Germany), AGE (Buchholz, Germany), and AGEM (Berlin, Germany). M Doerk received travel grants from travel grants from Gedeon Richter (Budapest, Hungary), Organon (Jersey City, USA) and Eisai (Tokyo, Japan) and is a member of DGGG (Berlin, Germany), AGE (Buchholz, Germany), Deutsche Gesellschaft für Senologie (Berlin, Germany). EF Solomayer is receiving: grants from the University of Saarland, and Storz and Erbe; personal fees and other compensation from Roche (Basel, Switzerland), Pfizer (New York City, NY, USA), Celgene (Summit USA), Amgen (Thousand Oaks, CA, USA), and Astra Zeneca (Cambridge, UK); and other fees from Esai (Tokyo, Japan), Johnson & Johnson (New Brunswick, NJ, USA), Novartis (Basel, Switzerland), Tesaro (Waltham, MA, USA), Teva (Petach Tikwa, Israel), Medac GmbH (Wedel, Germany), MSD (Kenilworth, NJ, USA), Vifor (Sankt Gallen, Switzerland), Gedeon Richter (Budapest, Hungary), Takeda (Tokyo, Japan), and AGE (Buchholz, Germany); other potential conflicts: Clovis Oncology (Boulder, Colorado, USA), Genomic Health (Redwood City, California, USA), Jenapharm (Jena, Germany), Matramed (Bexbach, Germany), Mentor (Minneapolis, Minnesota, USA), Pharma Mar (Mardid, Spain), Samsung (Suwon, Southkorea), University of Saarland (Saarbrücken, Germany), DGGG (Berlin, Germany), AGO (Taufkirchen, Germany), AGUB (Taufkirchen, Germany), DGS (Berlin, Germany), DKG (Berlin, Germany), Saarländisches Tumorzentrum am UKS e.V., University of Saarland, Homburg, Germany), Saarländische Krebsgesellschaft (Saarbrücken, Germany), Stiftung Endometriose Forschung (Westerstede, Germany), ESGE (Leuven, Belgium), ETC (Saarbrücken, Germany), DEGUM (Berlin, Germany), Deutsche Kontinenzgesellschaft (Frankfurt, Germany), BLFG (Berlin, Germany), Medconcept (Neustadt an der Weinstraße, Germany), Thieme (Stuttgart, Germany). MP Nigdelis received honoraria from RG Ärztefortbildung GmbH, as well as travel grants from Organon (Jersey City, USA). B Haj Hamoud received travel grants from Gedeon Richter, Astrazeneca (Cambridge, UK); Johnson & Johnson (New Brunswick, NJ, USA) and Storz (Tuttlingen, Germany) and is member of DGGG (Berlin, Germany), AGE (Buchholz, Germany) and Stiftung Endometriose Forschung (Westerstede, Germany). RM Sima declare to have no conflict of interest.
: The authors asked the local Institutional review board [IRB (Ethikkommission der Ärztekammer des Saarlandes, Saarbrücken, Germany)] if an approval is necessary. No approval was required from the IRB. The participants performed the course within their regular curriculum.